Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1 Name and Address of Company
Aeterna Zentaris Inc. (the “Company”)
c/o Stikeman Elliott LLP
1155 René-Lévesque Blvd. West, 41st Floor
Montréal, Québec
H3B 3V2
Item 2 Date of Material Change
November 16, 2018.
Item 3 News Release
On November 19, 2018, the Company issued a news release indicating the material change, which was disseminated on the GlobeNewswire news service.
Item 4 Summary of Material Change
On November 19, 2018, the Company announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending a marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency. The recommendation will now be reviewed by the European Commission.
Item 5.1 Full Description of Material Change
On November 19, 2018, the Company announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending a marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency. The recommendation will now be reviewed by the European Commission.
Item 5.2 Disclosure for Restructuring Transactions
Not applicable.
Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable.
Item 7 Omitted Information
Not applicable.
Item 8 Executive Officer
Further information regarding the matter described in this report may be obtained from Leslie Auld, Chief Financial Officer, at 843-900-3201 or IR@AEZSinc.com.
Item 9 Date of Report
November 20, 2018.
